Tipifarnib is a small molecule commercialized by Kura Oncology, with a leading Phase III program in Peripheral T-Cell Lymphomas (PTCL). According to Globaldata, it is involved in 54 clinical trials, of which 45 were completed, 4 are ongoing, and 5 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Tipifarnib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Tipifarnib is expected to reach an annual total of $110 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Tipifarnib (Zarnestra) is under development for the treatment of non-small cell lung cancer, salivary gland cancer, angioimmunoblastic T-cell lymphoma, thyroid/solid tumors with HRAS mutations, follicular T-cell lymphoma (FTCL), relapsed/refractory peripheral T cell lymphoma (PTCL), clear cell renal cell carcinoma, extranodal natural killer T-cell lymphoma, lower risk myelodysplastic syndrome, undifferentiated myeloproliferative disorders, chronic myelocytic leukemia, chronic myelomonocytic leukemia (CMML) and HRAS mutant urothelial cancer. The drug candidate is administered orally. It is a nonpeptidomimetic quinolinone. Tipifarnib is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development.
It was also under development for the treatment of solid tumor, relapsed or refractory multiple myeloma, acute myeloid leukemia, advanced pancreatic cancer, higher risk myelodysplastic syndrome, breast cancer, glioblastoma multiforme, relapsed /refractory lymphomas including diffuse large b-cell lymphoma, mantle cell lymphoma, sezary syndrome , Hodgkin lymphoma, mycosis fungoides, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma),nodal marginal zone B-cell lymphoma, splenic marginal zone b-cell lymphoma,refractory anemia with excess blasts in transformation and anaplastic large cell lymphoma, recurrent head and neck cancer squamous cell carcinoma including oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) and Hepatitis Delta virus (HDV) infections.
Kura Oncology Overview
Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor to treat acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.
The operating loss of the company was US$139.9 million in FY2022, compared to an operating loss of US$131.5 million in FY2021. The net loss of the company was US$135.8 million in FY2022, compared to a net loss of US$130.5 million in FY2021.
For a complete picture of Tipifarnib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.